NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016, 68019 [2016-23719]

Download as PDF sradovich on DSK3GMQ082PROD with NOTICES Federal Register / Vol. 81, No. 191 / Monday, October 3, 2016 / Notices in the survey is voluntary. Although the names of the participating entities might be disclosed in the summary memo and the memo might contain information provided to the Board for internal use only, exemption 4 of the Freedom of Information Act (5 U.S.C. 552(b)(4)) may exempt this information from disclosure to the public. However, if the information collected on the FR 1374 does not meet these standards for confidentiality (for example if the information collected is already public), it would not be granted confidential treatment. 2. Report title: Domestic Finance Company Report of Consolidated Assets and Liabilities. Agency form number: FR 2248. OMB control number: 7100–0005. Frequency: Monthly, quarterly, and semi-annually. Respondents: Domestic finance companies and mortgage companies. Estimated number of respondents: 450. Estimated average hours per response: Monthly, 20 minutes; Quarterly, 30 minutes; Addendum, 10 minutes. Estimated annual burden hours: 750 hours. General Description of Report: The FR 2248 is collected monthly as of the last calendar day of the month from a stratified sample of finance companies. Each monthly report collects balance sheet data on major categories of consumer and business credit receivables and on major short-term liabilities. For quarter-end months (March, June, September, and December), additional asset and liability items are collected to provide a full balance sheet. A supplemental section collects data on securitized assets. The data are used to construct universe estimates of finance company holdings, which are published in the monthly statistical releases Finance Companies (G.20) and Consumer Credit (G.19), in the quarterly statistical release Flow of Funds Accounts of the United States (Z.1), and in the Federal Reserve Bulletin (Tables 1.51, 1.52, and 1.55). Legal authorization and confidentiality: The Board’s Legal Division has determined that the FR 2248 is authorized by law pursuant to Section 2A of the Federal Reserve Act, 12 U.S.C. 225a). The obligation to respond is voluntary. Individual respondent data are confidential under section (b)(4) of the Freedom of Information Act (5 U.S.C. 552(b)(4)). VerDate Sep<11>2014 17:56 Sep 30, 2016 Jkt 241001 Board of Governors of the Federal Reserve System, September 28, 2016. Robert deV. Frierson, Secretary of the Board. [FR Doc. 2016–23781 Filed 9–30–16; 8:45 am] BILLING CODE 6210–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [CDC–2015–0034, Docket Number NIOSH 233–A] NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016 National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of issuance of final guidance publication. AGENCY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), announces the availability of the following publication: NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016 [2016–161]. ADDRESSES: This document may be obtained at the following link: http:// www.cdc.gov/niosh/docs/2016-161/. FOR FURTHER INFORMATION CONTACT: Barbara A. MacKenzie, NIOSH Division of Applied Research and Technology, 1090 Tusculum Avenue, MS C–26, Cincinnati, OH 45226. 513–533–8132 (not a toll free number), bmackenzie@ cdc.gov. SUMMARY: Dated: September 27, 2016. Frank Hearl, Chief of Staff, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2016–23719 Filed 9–30–16; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 68019 The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Provocative Questions—PQ2. Date: October 20, 2016. Time: 12:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 6W030, Rockville, MD 20850, (Telephone Conference Call). Contact Person: Zhiqiang Zou, MD, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W242, Rockville, MD 20892–9750, 240–276–6372, zouzhiq@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Regional Centers of Research, Excellence in Non-Communicable Diseases in Low and Middle Income Countries. Date: October 25, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review Officer, Office of Referral, Review and Program Coordination, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W530, Rockville, MD 20892–9750, 240–276–5856, ss537t@nih.gov Name of Committee: National Cancer Institute Special Emphasis Panel; Innovative Molecular Analysis Technologies (IMAT). Date: October 27–28, 2016. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Reed A. Graves, Ph.D., Scientific Review Officer, Research and Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room E:\FR\FM\03OCN1.SGM 03OCN1

Agencies

[Federal Register Volume 81, Number 191 (Monday, October 3, 2016)]
[Notices]
[Page 68019]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23719]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC-2015-0034, Docket Number NIOSH 233-A]


NIOSH List of Antineoplastic and Other Hazardous Drugs in 
Healthcare Settings 2016

AGENCY: National Institute for Occupational Safety and Health (NIOSH), 
Centers for Disease Control and Prevention (CDC), Department of Health 
and Human Services (HHS).

ACTION: Notice of issuance of final guidance publication.

-----------------------------------------------------------------------

SUMMARY: The National Institute for Occupational Safety and Health 
(NIOSH) of the Centers for Disease Control and Prevention (CDC), 
announces the availability of the following publication: NIOSH List of 
Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016 
[2016-161].

ADDRESSES: This document may be obtained at the following link: http://www.cdc.gov/niosh/docs/2016-161/.

FOR FURTHER INFORMATION CONTACT: Barbara A. MacKenzie, NIOSH Division 
of Applied Research and Technology, 1090 Tusculum Avenue, MS C-26, 
Cincinnati, OH 45226. 513-533-8132 (not a toll free number), 
bmackenzie@cdc.gov.

    Dated: September 27, 2016.
Frank Hearl,
Chief of Staff, National Institute for Occupational Safety and Health, 
Centers for Disease Control and Prevention.
[FR Doc. 2016-23719 Filed 9-30-16; 8:45 am]
 BILLING CODE 4163-19-P